Vi-one

Vi-one Biotech is a clinical-stage biotechnology company specializing in the development of next-generation mucosal vaccines using a proprietary parainfluenza virus 5 (PIV5) vector platform. The company's primary focus is on respiratory infectious diseases, with its lead candidate being a needle-free, intranasal vaccine for COVID-19. By leveraging the PIV5 platform, Vi-one aims to induce robust mucosal immunity at the site of infection, potentially providing superior protection against transmission compared to traditional injectable vaccines. The company operates in close collaboration with its US-based affiliate, CyanVac, to advance its pipeline of viral vector-based therapeutics and prophylactics. Vi-one is backed by prominent venture capital firms including Legend Capital and Northern Light Venture Capital.